194 related articles for article (PubMed ID: 38039052)
1. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.
Stolbach AI; Mazer-Amirshahi ME; Nelson LS; Cole JB
Clin Toxicol (Phila); 2023 Nov; 61(11):952-955. PubMed ID: 38039052
[TBL] [Abstract][Full Text] [Related]
2. American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time.
Stolbach AI; Mazer-Amirshahi M; Nelson LS; Cole JB
J Med Toxicol; 2024 Jan; 20(1):64-67. PubMed ID: 38032431
[No Abstract] [Full Text] [Related]
3. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement.
Infante AF; Elmes AT; Gimbar RP; Messmer SE; Neeb C; Jarrett JB
Int J Drug Policy; 2024 Feb; 124():104323. PubMed ID: 38232438
[TBL] [Abstract][Full Text] [Related]
4. Treatment of opioid overdose: current approaches and recent advances.
Britch SC; Walsh SL
Psychopharmacology (Berl); 2022 Jul; 239(7):2063-2081. PubMed ID: 35385972
[TBL] [Abstract][Full Text] [Related]
5. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
Krieter P; Gyaw S; Crystal R; Skolnick P
J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.
Dale O
Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):203-217. PubMed ID: 35500297
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose.
Crystal R; Ellison M; Purdon C; Skolnick P
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):58-69. PubMed ID: 37496452
[TBL] [Abstract][Full Text] [Related]
8. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
Strickland JC; Marks KR; Smith KE; Ellis JD; Hobelmann JG; Huhn AS
Int J Drug Policy; 2022 Aug; 106():103751. PubMed ID: 35636070
[TBL] [Abstract][Full Text] [Related]
9. Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021.
Rock P; Slavova S; Westgate PM; Nakamura A; Walsh SL
Drug Alcohol Depend; 2024 Feb; 255():111062. PubMed ID: 38157702
[TBL] [Abstract][Full Text] [Related]
10. High-dose naloxone formulations are not as essential as we thought.
Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN
Harm Reduct J; 2024 May; 21(1):93. PubMed ID: 38741224
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
Kaplan JL; Marx JA; Calabro JJ; Gin-Shaw SL; Spiller JD; Spivey WL; Gaddis GM; Zhao N; Harchelroad FP
Ann Emerg Med; 1999 Jul; 34(1):42-50. PubMed ID: 10381993
[TBL] [Abstract][Full Text] [Related]
12. On the front lines of the opioid epidemic: Rescue by naloxone.
Skolnick P
Eur J Pharmacol; 2018 Sep; 835():147-153. PubMed ID: 30092179
[TBL] [Abstract][Full Text] [Related]
13. Naloxone interventions in opioid overdoses: a systematic review protocol.
Shaw LV; Moe J; Purssell R; Buxton JA; Godwin J; Doyle-Waters MM; Brasher PMA; Hau JP; Curran J; Hohl CM
Syst Rev; 2019 Jun; 8(1):138. PubMed ID: 31186071
[TBL] [Abstract][Full Text] [Related]
14. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review.
Moe J; Godwin J; Purssell R; O'Sullivan F; Hau JP; Purssell E; Curran J; Doyle-Waters MM; Brasher PMA; Buxton JA; Hohl CM
CJEM; 2020 Mar; 22(2):178-186. PubMed ID: 31955714
[TBL] [Abstract][Full Text] [Related]
15. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
[TBL] [Abstract][Full Text] [Related]
16. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments.
Miner NB; Schutzer WE; Zarnegarnia Y; Janowsky A; Torralva R
Drug Alcohol Depend; 2021 Oct; 227():108974. PubMed ID: 34492557
[TBL] [Abstract][Full Text] [Related]
19. Countermeasures for Preventing and Treating Opioid Overdose.
France CP; Ahern GP; Averick S; Disney A; Enright HA; Esmaeli-Azad B; Federico A; Gerak LR; Husbands SM; Kolber B; Lau EY; Lao V; Maguire DR; Malfatti MA; Martinez G; Mayer BP; Pravetoni M; Sahibzada N; Skolnick P; Snyder EY; Tomycz N; Valdez CA; Zapf J
Clin Pharmacol Ther; 2021 Mar; 109(3):578-590. PubMed ID: 33113208
[TBL] [Abstract][Full Text] [Related]
20. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
